# US 2026/0226025 A1 · Pharmaceutically acceptable salt and crystal form of triazole compound, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226025 A1
- Document ID: US20260226025A1
- Status: Published application
- Kind: A1
- Application number: 19/147,859
- Filed: 2024-01-19
- Published: 2026-08-06
- Earliest claimed: 2023-01-19
- Assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Applicants: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Inventors: Lina JIA; Jie WANG; Junran YANG; Zhenxing DU; Jie WANG
- Web page: https://patentgrep.com/patent/US20260226025A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- C07C 215/08: with only one hydroxy group and one amino group bound to the carbon skeleton
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to a pharmaceutically acceptable salt and a crystal form of a triazole compound, and a preparation method therefor. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt and a crystal form of the compound (1S,3aS,5S,6aR)-5-((6-(5-(((4-(methoxymethyl)pyrimidin-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)-2-methylpyridin-3-yl)oxy) octahydrocyclopentadien-1-carboxylic acid of formula I, and a preparation method therefor. The corresponding salt has a good stability and can be better used in clinical treatment.

## Claims

### Claim 1

A crystal form A or B of the compound represented by formula I:
wherein (1) an X-ray powder diffraction pattern of the crystal form A, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.534, 10.223, 14.364, 17.269, 18.495, and 19.553;
(2) an X-ray powder diffraction pattern of the crystal form B, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.437, 10.381, 14.955, and 17.513;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 2

(canceled)

### Claim 3

A pharmaceutically acceptable salt of the compound represented by formula I, wherein the pharmaceutically acceptable salt is selected from the group consisting of a sodium salt and an ethanolamine salt:

### Claim 4 (depends on 3)

The pharmaceutically acceptable salt according to claim 3, wherein the chemical ratio of the compound represented by formula I to alkali ions is 1:1.

### Claim 5 (depends on 3)

A preparation method for a pharmaceutically acceptable salt of the compound represented by I according to claim 3, comprising a step of reacting the compound represented by I with a base, wherein the base is selected from the group consisting of sodium hydroxide and ethanolamine:

### Claim 6 (depends on 3)

A crystal form I or II of a sodium salt of the compound represented by formula I according to claim 3,
wherein (1) an X-ray powder diffraction pattern of the crystal form I, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 6.446, 8.350, 8.847, 9.335, 12.845, 16.901, and 17.874;
(2) an X-ray powder diffraction pattern of the crystal form II, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 6.771, 13.464, 13.970, 14.419, 15.593, 18.044, and 19.952;
wherein 2θ angles have a margin of error of +0.2.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising the following components:
i) the crystal form of the compound represented by formula I according to claim 1; and
ii) one or more pharmaceutically acceptable excipients.

### Claim 10 (depends on 1)

A method for preparing a pharmaceutical composition, comprising a step of mixing the crystal form of the compound represented by formula I according to claim 1 with a pharmaceutically acceptable excipient.

### Claim 11 (depends on 1)

A method of preventing and/or treating a LPA1-related disease in a subject in need thereof, the method comprising: administering a therapeutically effective amount of the crystal form of the compound represented by formula I according to claim 1.

### Claim 12 (depends on 1)

A method of treating and/or preventing fibrotic diseases of organs, respiratory diseases, renal diseases, hepatic diseases, inflammatory diseases, neurological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pain, urological diseases, ophthalmic diseases, metabolic diseases, cancer, and transplant rejection in patients in a subject in need thereof, the method comprising: administering a therapeutically effective amount of the crystal form of the compound represented by formula I according to claim 1.

### Claim 13 (depends on 1)

The crystal form A or B of the compound represented by formula I according to claim 1,
wherein (1) an X-ray powder diffraction pattern of the crystal form A, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.534, 10.223, 14.364, 15.816, 16.678, 17.269, 18.495, and 19.553;
(2) an X-ray powder diffraction pattern of the crystal form B, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.437, 10.381, 14.717, 14.955, 17.513, 21.395, 22.607, and 23.221;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 14 (depends on 1)

The crystal form A or B of the compound represented by formula I according to claim 1,
wherein (1) an X-ray powder diffraction pattern of the crystal form A, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.534, 10.223, 14.364, 15.816, 16.678, 17.269, 18.495, 19.553, 21.043, 21.342, 23.647, and 25.965;
(2) an X-ray powder diffraction pattern of the crystal form B, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 7.437, 10.381, 14.717, 14.955, 17.513, 18.466, 21.395, 21.692, 22.607, 23.221, and 25.972;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 15 (depends on 1)

The crystal form A or B of the compound represented by formula I according to claim 1,
wherein (1) an X-ray powder diffraction pattern of the crystal form A, the X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, of the crystal form is shown in FIG. 2;
(2) an X-ray powder diffraction pattern of the crystal form B, the X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, of the crystal form is shown in FIG. 3;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 16 (depends on 3)

The crystal form I or II of a sodium salt of the compound represented by formula I according to claim 3,
wherein (1) an X-ray powder diffraction pattern of the crystal form I, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 6.446, 8.350, 8.847, 9.335, 9.807, 12.845, 13.328, 13.739, 15.728, 16.901, and 17.874;
(2) an X-ray powder diffraction pattern of the crystal form II, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 6.771, 11.446, 13.464, 13.970, 14.419, 15.593, 18.044, 19.952, and 24.260;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 17 (depends on 3)

The crystal form I or II of a sodium salt of the compound represented by formula I according to claim 3,
wherein (1) an X-ray powder diffraction pattern of the crystal form I, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 4.741, 6.446, 8.350, 8.847, 9.335, 9.807, 12.845, 13.328, 13.739, 15.728, 16.901, 17.874, 19.059, and 19.805;
(2) an X-ray powder diffraction pattern of the crystal form II, expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 6.771, 8.505, 11.446, 13.464, 13.970, 14.419, 15.593, 18.044, 19.952, 20.313, 22.868, 24.260, and 32.304;
wherein 2θ angles have a margin of error of ±0.2.

### Claim 18 (depends on 3)

The crystal form I or II of a sodium salt of the compound represented by formula I according to claim 3,
wherein (1) an X-ray powder diffraction pattern of the crystal form I, the X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, of the crystal form is shown in FIG. 5.;
(2) an X-ray powder diffraction pattern of the crystal form II, the X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, of the crystal form is shown in FIG. 6.;
wherein 2θ angles have a margin of error of ±0.2.
